Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

Utthara Nayar(Broad Institute), Ofir Cohen(Broad Institute), Christian Kapstad(Broad Institute), Michael S. Cuoco(Broad Institute), Adrienne G. Waks(Broad Institute), Seth A. Wander(Broad Institute), Corrie Painter(Broad Institute), Samuel S. Freeman(Broad Institute), Nicole S. Persky(Broad Institute), Lori Marini(Dana-Farber Cancer Institute), Karla Helvie(Dana-Farber Cancer Institute), Nelly Oliver(Dana-Farber Cancer Institute), Orit Rozenblatt–Rosen(Broad Institute), X. Cynthia(Washington University in St. Louis), Aviv Regev(Broad Institute), Eric P. Winer(Brigham and Women's Hospital), Nancy U. Lin(Brigham and Women's Hospital), Nikhil Wagle(Broad Institute)
Nature Genetics
November 30, 2018
Cited by 238

Abstract


Related Papers

No related papers found

Powered by citation graph analysis